Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps.

Hanna K Mandl, Jessa E Miller, Daniel M Beswick

Otolaryngologic clinics of North America 2024 Apr

filter terms:

A substantial portion of asthma and nasal polyps (NPs) share a common pathogenesis, which includes type 2-mediated inflammation. Distinct endotypes and phenotypes characterizing asthma and chronic rhinosinusitis have been identified. With emerging evidence describing pathophysiology, novel targets for biologic monoclonal antibody treatments have been developed. There are currently six biologic therapies approved by the US Food and Drug Administration to treat asthma, including omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab, three of these-omalizumab, mepolizumab, and dupilumab-are also approved for NPs. Copyright © 2023 Elsevier Inc. All rights reserved.

Citation

Hanna K Mandl, Jessa E Miller, Daniel M Beswick. Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps. Otolaryngologic clinics of North America. 2024 Apr;57(2):225-242